Effect of Candida Rugosa Lipase on Serum Triglyceride Lowering
NCT05295134 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39
Last updated 2022-03-24
Summary
The primary objective of this study was to evaluate the safety and tolerability of 3 doses of fungal lipase in the treatment of adults with mildly elevated serum triglycerides. The secondary objective was to assess the efficacy of fungal lipase in reducing serum triglycerides in adults with mildly elevated serum triglycerides.
Conditions
- Hypertriglyceridemia
Interventions
- DIETARY_SUPPLEMENT
-
Placebo
Participants were directed to consume 1 placebo capsule containing maltodextrin, three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
- DIETARY_SUPPLEMENT
-
Candida cylindracea lipase (225,000 FIP lipase units per day)
Participants were directed to consume 1 capsule containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
- DIETARY_SUPPLEMENT
-
Candida cylindracea lipase (450,000 FIP lipase units per day)
Participants were directed to consume 2 capsules containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
- DIETARY_SUPPLEMENT
-
Candida cylindracea lipase (675,000 FIP lipase units per day)
Participants were directed to consume 2 capsules containing lipase (112,500 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
Sponsors & Collaborators
-
Atlantia Food Clinical Trials
collaborator INDUSTRY -
Cork University Hospital
collaborator OTHER -
BIO-CAT, Inc.
lead INDUSTRY
Principal Investigators
-
Fergus Shanahan, MD, PhD · Cork University Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2014-03-13
- Primary Completion
- 2014-10-06
- Completion
- 2014-11-04
Countries
- Ireland
Study Locations
More Related Trials
-
Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD)
NCT01511523 ·Status: UNKNOWN ·Phase: NA
-
Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children
NCT01529268 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Liver Adiposity Effects on Pediatric Statin
NCT04903223 ·Status: RECRUITING ·Phase: PHASE1
-
Clinical Study on the Safety of CNT-02 for TGCV and NLSD-M
NCT02830763 ·Status: TERMINATED ·Phase: NA
-
Testing the Potential Metabolic Effect of the Human Gut Bacterial Peptide, RUCILP, in Healthy Men
NCT06923839 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Cholic Acid for Hepatic Steatosis in Lipodystrophy
NCT00457639 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis
NCT00432861 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis
NCT00004441 ·Status: COMPLETED ·Phase: NA
-
Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus
NCT02871882 ·Status: COMPLETED ·Phase: PHASE2
-
Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)
NCT03632993 ·Status: COMPLETED ·Phase: PHASE2
-
Migalastat Food Effect Study
NCT01489995 ·Status: COMPLETED ·Phase: PHASE1
-
ButyraGen™, Short Chain Fatty Acids and Gut Microbiome
NCT05601635 ·Status: COMPLETED ·Phase: NA
-
Dietary Supplementation With Butyrate in Individuals With Liver Steatosis and Metabolic Syndrome
NCT06398522 ·Status: COMPLETED ·Phase: NA
-
Phase I Trial of Silymarin for Chronic Liver Diseases
NCT00389376 ·Status: COMPLETED ·Phase: PHASE1
-
Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy
NCT03168555 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Bile Acids on the Secretion of Satiation Peptides in Humans
NCT01674946 ·Status: COMPLETED ·Phase: PHASE1
-
The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis
NCT01791959 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Bile Acids in Patients With Peroxisomal Disorders
NCT00004442 ·Status: TERMINATED ·Phase: NA
-
Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)
NCT02598128 ·Status: COMPLETED ·Phase: NA
-
The Effect of a Probiotic on Hepatic Steatosis
NCT00099723 ·Status: TERMINATED ·Phase: PHASE1
-
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
NCT00281502 ·Status: UNKNOWN ·Phase: PHASE2
-
Intralumenal Effects on Cholesterol Absorption/Synthesis
NCT00328211 ·Status: COMPLETED ·Phase: NA
-
Dietary Glycine Supplementation in Metabolic Dysfunction-associated Steatotic Liver Disease
NCT07285135 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Carnitine and Liver Mitochondria Fatty Acid Processing
NCT03193125 ·Status: COMPLETED ·Phase: NA
-
Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished Children
NCT04542473 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3